<DOC>
	<DOC>NCT01491113</DOC>
	<brief_summary>This is a human pharmacology, single-dose study to investigate the pharmacokinetics of orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and in Japanese subjects with various degrees of impaired renal function.</brief_summary>
	<brief_title>Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients</brief_title>
	<detailed_description>The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam (ucb L059) and its metabolite (ucb L057) after a single dose of LEV 250 mg or LEV 500 mg in Japanese subjects with normal renal function and in Japanese subjects with various degrees of renal impairment.</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Healthy subjects with normal renal function Subject is Japanese Subjects with creatinine clearance within 1 of 3 Groups (CLcr[mL/min/1.73 cm^2]: Group B: 50 &lt;80, Group C: 30 &lt;50, Group D: &lt;30), or for Group E, subjects with endstage renal failure undergoing hemodialysis Subjects has taken any drug treatment, disease or injury to influence Levetiracetam PK except for renal impairments</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Oral administration</keyword>
	<keyword>Japanese</keyword>
	<keyword>Non-epileptic</keyword>
	<keyword>Healthy</keyword>
	<keyword>Renal impaired subjects</keyword>
</DOC>